Revision of PRECAUTIONS

Olmesartan medoxomil
Olmesartan medoxomil/azelnidipine
Valsartan
Valsartan/amlodipine besilate
Valsartan/cilnidipine
Valsartan/hydrochlorothiazide

September 9, 2025

Therapeutic category

Antihypertensives

Non-proprietary name

Olmesartan medoxomil

Olmesartan medoxomil/azelnidipine

Valsartan

Valsartan/amlodipine besilate

Valsartan/cilnidipine

Valsartan/hydrochlorothiazide

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
Angioedema	Angioedema
Symptoms such as swelling of the face, lip, pharynx, and tongue may	Symptoms such as swelling of the face, lip, pharynx, and tongue may
occur.	occur. Of note, intestinal angioedema accompanied by abdominal
	pain, queasy, vomiting, diarrhoea, etc. may occur.